By Josh Beckerman

AstraZeneca PLC reported positive results from a Phase III trial of once-weekly exenatide in adolescents aged 10-17 with type 2 diabetes.

The trial met its primary endpoint, significantly reducing blood sugar versus placebo. Data at week 24 showed the drug was generally well-tolerated, the company said.

Exenatide extended release was first approved in the U.S. for type 2 diabetes in adults in January 2012.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

June 25, 2021 14:31 ET (18:31 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.